Intensive care unit-acquired weakness (ICUAW) is an increasingly recognised consequence of critical illness. ICUAW is associated with a significant morbidity and mortality independent of the severity of the primary illness, 1 despite this our understanding of the aetiology, pathology and potential management options of this disease is limited.
Introduction
Intensive care unit-acquired weakness (ICUAW) is an increasingly recognised consequence of critical illness. ICUAW is associated with a significant morbidity and mortality independent of the severity of the primary illness, 1 despite this our understanding of the aetiology, pathology and potential management options of this disease is limited.
Growth and differentiation factor 15 (GDF-15), a member of the transforming growth factor-b (TGF-b) family, is a stress-induced cytokine. 2 GDF-15 is released from tissues in response to inflammation, oxidative stress and hypoxia. 2, 3 GDF-15 was anti-apoptotic and prevented hypertrophy of cardiac myocytes in vitro 4 and over-expression caused cachexia in murine tumour models. 5 MicroRNAs are essential for muscle homeostasis, dysregulation has been described in muscle disorders, 6 their expression can be influenced by inflammatory cytokines 7 and microRNAs may down-regulate TGF-b signalling. 8 However, the function of microRNAs in ICUAW has not been described. We hypothesised that down-regulation of muscle microRNAs, driven by GDF-15, would lead to increased sensitivity to TGF-b signalling in muscle of critically ill patients thereby causing ICUAW.
Identification of GDF-15 as a potential driver of muscle loss in the critically ill
Objectives: In a novel human model of acute muscle wasting following cardiac surgery, potential circulating modulators of muscle mass: insulinlike growth factor-1 (IGF-1), myostatin and growth and differentiation factor-15 (GDF-15), were measured over a week. We hypothesised that patients who developed acute muscle wasting would show distinct patterns of change in these mediators.
Methods: We conducted a prospective study of 42 patients undergoing elective cardiothoracic surgery and identified those who developed muscle wasting. Serial blood samples were taken to quantify changes in circulating levels of insulin-like growth factor-1 (IGF-1), myostatin and GDF-15.
Results: A total of 23 of 42 patients (55%) developed quadriceps atrophy. There was an acute decrease in IGF-1 and unexpectedly myostatin, known mediators of muscle hypertrophy and atrophy, respectively. 9 By contrast, plasma GDF-15 concentrations increased in all patients. This increase in GDF-15 was sustained at day 7 in those who developed muscle wasting (day 7 compared with baseline, p<0.01), but recovered in the non-wasting group (p>0.05). IGF-1 did not recover in those who developed muscle wasting (day 7 compared with baseline, p<0.01) but did in the non-wasting group (p>0.05). 10 
GDF-15 down-regulation of muscle microRNA drives increased sensitivity to TGF-b signalling in ICUAW
Objectives: In this study we investigated the potential mechanisms by which GDF-15 may contribute to the development of ICUAW.
Methods: We conducted an observational study of 20 patients with ICUAW and seven elective surgical controls. Subjects underwent rectus femoris muscle biopsy and blood sampling. Muscle specimens were examined for mRNA and microRNA expression of target genes by qPCR: sections were stained for pSMAD2/3 nuclear positivity as a marker of TGF-b signalling. GDF-15 concentration was quantified in plasma (ELISA). To examine the effects of GDF-15 on target genes, differentiated C2C12 myotubes were treated with GDF-15 for four days. The effect of over-expression of miR-181a in C2C12 myoblasts on TGF-signalling was also examined.
Results: Compared with controls, GDF-15 mRNA expression in muscle (median 2-fold higher; p=0.006) and concentration in plasma (median 7239 vs 2454 pg/ml; p=0.001) was greater in patients with ICUAW ( Figure  1) . Expression of microRNA involved in muscle homeostasis was significantly lower in patients with ICUAW. Both log[GDF-15 mRNA] and log[plasma GDF-15] were significantly negatively correlated with log[microRNA expression]. GDF-15 treatment of myotubes significantly elevated expression of atrophy-related genes and down-regulated expression of microRNAs. MiR-181a suppressed TGF-b responses in myoblasts, suggesting increased sensitivity to TGF-b in ICUAW muscle. Consistent with this, nuclear phospho-SMAD2/3 and CYR61 mRNA expression were increased in ICUAW muscle. Figure 1A represents 1,200 pg/mL -the upper limit of normal plasma GDF-15. Data shown as median and interquartile range; ** p<0.01, *** p<0.001 -Mann-Whitney. Correlation of plasma GDF-15 with sequential organ failure score (SOFA) at the time of sampling (C), r= Pearson's r value for correlation.
MiR-181a: a potential biomarker of acute muscle wasting in the critically ill
Finally, a rise in circulating miR-181a two days after cardiac surgery represented a potential biomarker of acute muscle wasting. These data need to be reproduced in a larger validation cohort of patients.
Discussion
These data suggest that acute muscle loss occurs as a result of an imbalance between drivers of muscle atrophy and hypertrophy, and that GDF-15 is a potential driver of acute muscle loss following cardiac surgery. Our second study provides a potential mechanism by which GDF-15 may drive muscle loss in ICUAW. In summary, by suppressing expression of muscle microRNAs, GDF-15 may increase sensitivity to TGF-b signalling, thus promoting muscle wasting in ICUAW (Figure 2) .
These data identify both GDF-15 and associated microRNA as potential therapeutic targets in ICUAW.
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This work is funded by an MRC Clinical fellowship to Dr Bloch and supported by the NIHR Respiratory BRU at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College. An integrated approach to assessing the mechanisms underlying sepsis-induced AKI and recovery N Arulkumaran Bloomsbury Institute of Intensive Care Medicine, University College London, UK Purpose Sepsis-induced acute kidney injury (AKI) remains an enigma in terms of pathogenesis, early diagnosis and recovery. Using a long-term animal model of sepsis (peritonitis) I thus sought to characterise changes in renal functionality, haemodynamics, bioenergetics and histology against a broad panel of plasma and urine biomarkers at multiple timepoints through the septic illness, including the recovery phase; and to compare and contrast results in eventual survivor and non-survivor animals.
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Background
Sepsis is the underlying cause of half the cases of AKI. Mortality in patients with septic AKI receiving renal replacement therapy (KDIGO AKI 3) is 8.5fold higher than in those without AKI. 1 While this may simply reflect a more severely ill patient, the degree of renal failure itself may be a major contributor to mortality. 1 The corollary is that early identification and prevention/amelioration of AKI will improve outcomes.
Unfortunately, standard tests for defining AKI are well recognised to be insensitive. Plasma creatinine rises only when 70-80% of renal function is lost. Our ability to estimate glomerular filtration rate (GFR) based on serum creatinine has limitations due to rapid fluctuations in kidney function, altered creatinine production and fluid balance. This has driven the development of multiple (>30) novel biomarkers intended to diagnose AKI at an earlier timepoint. However, few comparative studies have delineated temporal changes in these biomarker levels over the course of the septic illness. Furthermore, many confounding factors exist, including the frequent difficulty in timing the onset of the initial septic injury to determine which biomarkers change the earliest; non-specificity of the biomarker, eg Neutrophil gelatinase-associated lipocalin -NGAL -rises with neutrophil activation; the heterogeneous nature of 'critical illness'; and other contributing pathologies including drug toxicities, unrecognised hypovolaemia and underlying co-morbidities. It thus remains unknown which biomarkers are superior in terms of early identification of either renal injury and/or dysfunction. This is compounded by an incomplete understanding of the pathophysiology underlying AKI. Macrovascular and intrarenal microvascular haemodynamic alterations, and local inflammatory responses are all invoked. 2 Yet, as an important paradox, minimal histological change is a well-recognised phenomenon in septic AKI with little evidence of cell death in either patients or animal models. 3, 4 Surviving patients usually recover renal function within days-to-weeks such that they do not require chronic dialysis. However, recent data do suggest an increased risk of chronic renal failure in patients sustaining an AKI. 5 Thus, a better understanding of pathophysiological mechanism, improved delineation of the temporal changes in renal biomarkers across the septic illness (from initiation through to recovery), and an accurate prognostication of the degree of (impending) severity would greatly serve patient management.
Animal models offer the advantages of knowing precisely when the septic insult commenced, and the ready ability to obtain renal tissue for analysis. To be representative of the human condition, they have to simulate many of the physiological and pathological aspects of sepsis including a proper infectious insult, an adequate duration of study, and fluid resuscitation to avoid the consequences of untreated hypovolaemia leading to organ hypoperfusion.
Over many years the Singer lab has developed a long-term (three day) rat model of faecal peritonitis where animals are conscious and instrumented with tunnelled arterial and venous lines to enable continuous BP monitoring, fluid administration and intermittent blood sampling. Nonsurvivors generally die between 18-36 hours whereas those surviving to 72 hours generally show signs of clinical and biochemical recovery. This model offers a perfect opportunity to carefully explore the multiple facets of AKI.
Methods
The animal model was set-up as described. 6, 7 In brief, male Wistar rats (approx. 300-330 g body weight) underwent tunnelled carotid and jugular vascular line instrumentation under a short period of isoflurane anaesthesia. Faecal slurry was injected intraperitoneally and two hours later, fluid was commenced to maintain an adequate intravascular compartment and normoglycaemia.
At pre-defined timepoints (6, 12, 24, 48, 72 hours), animals (≥5 per group) underwent echocardiography, plus blood sampling for routine biochemistry, circulating pro-(IL-1b, IL-6, IFN-g), and anti-inflammatory (IL-4, IL-10) cytokines and a range of plasma and urine biomarkers indicative of renal injury or dysfunction. They were then sacrificed with kidneys taken for histological section and tissue cytokine (IL-1b, IL-10, MCP-1, IL-4, INF-g) analysis. Renal histology was assessed by light microscopy for features of tubular injury (dilated tubules, tubular casts, loss of brush border, cell necrosis), macrophage infiltration (CD68 staining) and cell death (TUNEL stain). Comparison was made against sham-operated controls and naïve animals.
In a separate study, animals were terminally anaesthetised at either six and 24 hours for measurement of cardiac output (echocardiography) plus renal haemodynamics. renal artery blood flow (ultrasonic flow probe), renal cortical tissue oxygen tension (Oxylite sensor), and the renal arteriovenous oxygen difference and renal oxygen extraction ratio (using arterial and renal venous blood sampling). Electron microscopy assessed mitochondrial ultrastructure at 24 hours.
Finally, to assess the effects of non-haemodynamic factors on renal bioenergetics, multiphoton confocal microscopy images were recorded over 45 minutes in intact renal sections taken from healthy rats incubated in either physiologic saline solution, sham or septic serum with or without the anti-oxidant 4-OH-Tempo (n=4). Pooled septic serum was obtained from five rats after 24 hours of sepsis. Various probes investigated changes in NADH redox state, reactive oxygen species (ROS) production and mitochondrial membrane potential (Figure 1) . 
Results
Overall mortality among septic rats (n=96) was 21%, with most deaths (76%) occurring between 18-36h. All controls (n=62) lived. In summary, in this model I found: 1. At 24 hours, when serum creatinine had peaked, acute tubular injury was mild and sporadic, with minimal renal tubular cell death. This confirms findings from patient biopsies. 2. At six hours, septic animals had a lower renal vascular resistance (RVR) but no significant differences in global or renal oxygen delivery (DO 2 ), renal blood flow, renal cortical PO 2 or renal oxygen extraction. However by 24 hours, RVR was similar, yet renal oxygen delivery was lower.
Despite this, renal oxygen extraction ratio was similar and associated with a lower renal cortical PO 2 . 3. While electron microscopy revealed preserved mitochondrial ultrastructure in renal proximal tubular epithelia of septic rats, mitochondrial dysfunction was seen in both proximal and distal tubular epithelial cells incubated in septic serum with increased production of reactive oxygen species (ROS) and falls in mitochondrial membrane potential. The increase in ROS production could be prevented by co-incubation with the ROS scavenger, 4-OH-Tempo. 4. A pro-inflammatory systemic response was maximal at six hours, with corresponding clinical features of pyrexia, tachycardia, and the lowest values of stroke volume. 5. These features had largely resolved by 24 hours, to be replaced by a progressive anti-inflammatory phenotypic dominance. This corresponded with recovery of cardiac function and normalization of core temperature. 6. The renal inflammatory phenotype differed from circulating cytokine levels. Monocyte chemoattractant protein-1 (MCP-1) is a key chemokine regulating migration and infiltration of monocytes/macrophages. IFN-g induce a pro-inflammatory 'M1' macrophage subtype, responsible for release of proinflammatory cytokines (eg IL-1b). In contrast, IL-4 induces an anti-inflammatory 'M2' macrophage subtype, responsible for releasing anti-inflammatory cytokines (eg IL-10, TGF-b). In the model I found renal MCP-1 peaked at six hours and this corresponded to an increase in renal macrophages, a peak in renal IFN-g, an increase in renal IL-1b (which remained elevated for 48 hours) and a nadir in renal IL-4. These data are consistent with an environment that polarizes macrophages towards the M1 subtype. The environment subsequently moved towards the M2 subtype; renal IL-4 levels rose sharply between 12-24 hours while renal IL-10 also increased, peaking at 48 hours. At the same time renal IFN-g fell. A second peak in renal MCP-1 was seen at 24 hours followed by a large influx of macrophages at 48 hours. At this point, serum creatinine was recovering and approaching baseline values. This implies the antiinflammatory phenotypic predominance within the kidney is associated with recovery of renal function, though cause-and-effect would need to be demonstrated. 7. The renal biomarkers showed a distinct pattern. Only urine markers associated with proximal tubular injury (NGAL, KIM-1, clusterin) were elevated from six hours onward, despite serum creatinine only increasing at 24 hours. On the other hand, markers of distal tubular injury (osteopontin, calbindin) and cell death (urine cystatin C) were not raised. Urine clusterin peaked earliest (at six hours) and remained elevated for 72 hours, whereas urine KIM-1 and urine NGAL peaked at 12 hours and 24 hours, respectively. 8. The sharp fall in urine KIM-1 and sharp rise in urine NGAL at 24 hours paralleled the increase in pro-resolution renal cytokines IL-4 and IL-10. The relative change in serum creatinine was minimal compared to that seen for KIM-1, clusterin, and NGAL. 9. Serum cystatin C, a marker of glomerular filtration, was unchanged at all time points
Conclusion
Using this rat model I have identified an early pro-inflammatory phenotype within the septic kidney that corresponded to worsening renal function, as indicated by both standard biochemistry and renal biomarkers of proximal tubular injury and dysfunction. Proximal tubules are located within the cortex which showed late (24 hours) evidence of tissue hypoxia though renal oxygen consumption as a whole was unaffected. Glomerular and distal tubular function appeared to be spared by the septic process. Notably, cell death was minimal and mitochondrial ultrastructure essentially normal, though a depressant effect of septic serum on renal mitochondria was noted ex vivo that could be blocked by an antioxidant.
The recovery phase -as demonstrated by clinical and biochemical improvement -was associated with a shift to an anti-inflammatory phenotype within the kidney and a normalisation of biomarkers reflective of proximal tubular injury/dysfunction.
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In summary, circulating humoral factors inducing intrarenal inflammation and bioenergetic depression appear more significant than haemodynamic perturbations in inducing AKI in this fluid-resuscitated rat model, with the proximal tubule being primarily targeted. Whether early promotion of an anti-inflammatory phenotype can indeed reverse/ ameliorate renal dysfunction requires further investigation.
The cost-effectiveness of prehospital triage and bypass for patients with suspected traumatic brain injury
GW Fuller University of Sheffield, Sheffield, UK
Background Traumatic brain injury (TBI) is a major public health problem in the UK, responsible for 3,000 deaths and 4,000 severe disabilities annually. 1 The costs of acute TBI care in England and Wales have been estimated at £1 billion per annum. 2 Socioeconomic costs resulting from loss of earnings and long term care requirements are many times greater. 3 Despite this enormous burden therapeutic advances in TBI care have been limited and interest has focused on optimising the organisation of neurotrauma services to improve outcomes. Regional trauma systems were recently introduced in England, bypassing patients with suspected significant TBI to neuroscience centres (NCs). 4 This approach expedites specialist care, but could risk secondary brain injury during prolonged primary transportation. Increasing the numbers of patients receiving NC care may also result in higher healthcare costs.
In 2007 the National Institute for Health and Care Excellence (NICE) guidelines on head injury highlighted the absence of valid evidence examining the clinical and cost-effectiveness of bypass and strongly recommended further research to support the adoption of this management strategy. 2
Aims
The aim of this investigation was to inform NHS decision making about how best to organise trauma services for adult patients with suspected significant TBI injured closest to a non-specialist hospital with initially stable airway, breathing, and circulation. Three related research questions were addressed: • Given available evidence what is the most cost-effective management strategy? • What is the uncertainty surrounding this choice? • Is it cost-effective to perform further research to reduce this decision uncertainty? A hybrid decision tree-state transition model was implemented to estimate the cost-effectiveness of competing strategies in terms of expected net monetary benefit and incremental cost per quality-adjusted life year (Incremental cost-effectiveness ratios, ICER). The base case model followed NICE reference case recommendations and was evaluated probabilistically to account for parameter uncertainty. 5 The impact of parameter and structural uncertainty was further examined in a series of scenario, threshold and one-way sensitivity analyses. Decision uncertainty was also examined using a cost effectiveness acceptability curve and frontier.
Methods
Expected value of perfect information (EVPI), and expected value of partial perfect information (EVPPI) were then calculated to inform future research prioritisation. 6 The expected value of sample information (EVSI) and the expected net benefit of sampling (ENBS) from conducting a definitive trial of bypass were also examined; 7 identifying the optimal sample size for a future study under a range of assumptions for disease incidence and study characteristics. 
Results
The base case probabilistic analysis suggested that routine transfer (transport to the local non-specialist hospital with routine secondary transfer of all patients with acute expanding intracranial haematomas or TBI requiring intensive care to a regional NC) may provide the optimal management strategy at a willingness to pay threshold of £20,000 (mean ICER £2,260). At a higher threshold of £30,000 pre-hospital triage and bypass was the most cost-effective option (mean ICER £27,158). At both thresholds there was considerable decision uncertainty, with a high probability of erroneously adopting a sub-optimal strategy (54% and 52% respectively, Figure 1) . Sensitivity analyses demonstrated that this result was critically dependent on the parameterisation of costs and effects for routine transfer and bypass strategies. Furthermore, alternative assumptions on life expectancy following injury, utility weights assigned to GOS health states, neurosurgery costs, and discounting rates all resulted in reversal of the adoption decision at λ=£20,000, and indicated bypass as the optimal strategy.
The considerable decision uncertainty, and important public health burden of TBI, was reflected in a large population EVPI result. Further research up to a value of £36 million may be indicated to eliminate parameter uncertainty and opportunity costs from making the wrong adoption decision at a cost-effectiveness threshold of £20,000. EVSI results suggested that, if feasible, a large scale trial examining the comparative effectiveness of bypass and selective secondary transfer is potentially costeffective. Maximal expected net benefit of sampling (£11.0 million) would be achieved with a trial of 520 patients per arm, randomised across eight ambulance services, and taking three years. Expected value of information results did not vary substantively in sensitivity analyses examining alternative estimates for the population that may benefit from future research and assumptions on trial characteristics.
Conclusions
This investigation provides the first comprehensive examination of the cost-effectiveness of bypass in patients with suspected significant TBI injured closest to a non-specialist hospital. It highlights the considerable uncertainty surrounding the optimal management pathway, and demonstrates that further research comparing bypass to secondary transfer strategies would have very high value to support decisions on reconfiguration of trauma services.
Furthermore, studies performed to inform model development provide information delineating the underlying mechanisms by which bypass may influence the outcomes of patients with suspected TBI, and report novel estimates for life expectancy and utility values that will benefit future TBI economic evaluations.
Characterising functional/phenotypic heterogeneity in blood and alveolar neutrophils (PMNs) in acute respiratory distress syndrome (ARDS)
JK Juss University of Cambridge, Cambridge, UK
Background
The acute respiratory distress syndrome (ARDS) is a leading cause of mortality and morbidity in intensive care unit (ICU) patients. It is characterised by diffuse alveolar inflammation resulting in severe hypoxemia, often necessitating mechanical ventilation. Despite improvements such as lung-protective ventilation, mortality remains high (20-45%) and to date there are no effective pharmacological strategies for this condition. 1 Neutrophilic (PMN) alveolitis is a key histopathological hallmark of ARDS. The intensity of alveolar PMN infiltration correlates with disease severity and with clinical outcome. Inappropriate accumulation and/or activation of PMNs within the alveoli is known to cause the unrestrained release of histotoxic oxygen radicals, proteases, neutrophil extracellular traps (NETs) and pro-inflammatory cytokines (ie GM-CSF, TNFa, IFNg, IL-1b, IL-2 and IL-6); this pro-inflammatory process is thought to underpin the complex pathophysiology of ARDS. PMN longevity increases dramatically during inflammation, but the precise molecular mechanisms governing this aberrant survival phenotype are incompletely understood. Previous studies have identified GM-CSF as the dominant PMN prosurvival mediator in ARDS. 2 While the complexity of the pathophysiologic response in ARDS is difficult to recapitulate in ex vivo studies using a single cytokine stimulus, such studies nonetheless provide valuable information. The cytoprotective effect of GM-CSF in PMNs is Class I phosphoinositide 3-kinase (PI3K)-dependent; pharmacological inhibition of Class I PI3Ks is predicted to restore PMN apoptosis and to inhibit the oxidative burst, 3 conferring potential benefit in ARDS and other neutrophil-dominant inflammatory diseases.
PMNs have traditionally been viewed as a homogenous population of short-lived cells with limited biosynthetic/transcriptional capacity and a fixed functional repertoire. More recently, the concepts of long-lived PMNs, retrograde transendothelial migration and PMN plasticity have emerged, demonstrating that PMNs display a significant de novo synthetic capacity and can differentiate into discrete subsets with distinct phenotypic/functional profiles. 4, 5 Given the technical challenges inherent in obtaining purified alveolar PMNs ( alv PMNs) in ARDS, the phenotype and functional activity of alveolar-sequestered PMNs in this condition are largely unknown. Historically, animal models or autologous blood PMNs ( blood PMNs) from patients with ARDS have been used as a proxy for alv PMNs.
Hypothesis
ARDS alv PMNs exist in a unique microenvironment and may display fundamentally distinct properties relative to autologous blood PMNs during inflammation. Identifying the precise functional abnormalities of alv PMNs in ARDS may facilitate targeted drug treatment with PI3K inhibitors to reduce tissue injury without compromising innate immune function.
Methods
Mechanically ventilated patients (n=23) fulfilling the Berlin criteria for ARDS underwent bronchoalveolar lavage (BAL) within 48 hours of ARDS onset. ARDS alv PMNs were isolated to 92±3.3% (%±SD) purity using a negative-selection immunomagnetic bead technique (Robosep ® ) and studied in a simultaneous and parallel manner with age-and gendermatched healthy volunteer (HV) blood PMNs. This paired sampling approach provided a robust experimental design in controlling for confounders.
PMN morphology was assessed using cytospins and modified Wright' s staining. PMNs were cultured with the panPI3K inhibitor ZSTK474 (10 M) or with vehicle control, and apoptosis was assessed at 20 hours by flow cytometry (AnnexinV staining). Basal PMN activation was assessed by flow cytometry (CD11b, CD62L) and F-actin staining (with rhodaminephalloidin). The kinetics of the oxidative burst in response to stimulation with fMLP, opsonized Streptococcus pneumonia and zymosan were determined using luminol-dependent chemiluminescence detection of reactive oxygen species (ROS). PMN phagocytosis was assessed using pHrodo™ RED Staphylococcus aureus. NETs were visualised by confocal fluorescence imaging using Sytox Green (an extracellular DNA dye) and staining for citrullinated histones.
Data were examined to determine if they were from a Gaussian distribution, and logarithmically transformed if necessary. Data were analysed using a mixed model ANOVA method, and p<0.05 was considered statistically significant.
Results
The mean age of patients was 56.0±16.4 years (±SD); eight (34.7%), 11 (47.8%) and four (17.39%) patients had mild, moderate and severe ARDS respectively. PMNs constituted 69.7±4.2% of the ARDS bronchoalveolar lavage. ARDS alv PMNs were phenotypically heterogenous, with a distinctive hyper-segmented (≥5 lobes) nuclear morphology (25.2±11.7% (%±SD)) compared to HV blood PMNs (4.8±1.9%) and ARDS blood PMNs (11.1±7.9%) (Figure 1A and B) . ARDS alv PMNs exhibit a reduction in spontaneous apoptosis at 20 hours (28.5±19.2% apoptotic) relative to autologous blood PMNs (48±5.8% apoptotic), and more so relative HV blood PMNs (70±2.8% apoptotic) (p<0.05 in both cases; Figure 1C) . The pro-survival phenotype observed in ARDS blood PMNs was partially sensitive to PI3K inhibition (54.5±23.6%). Surprisingly, the phagocytic capacity of alv PMNs to ingest Staphylococcus aureus was fully preserved (Figure 2A) ; there was a trend to a reduction in the oxidative burst to ingested particles but this did not reach statistical signficance (Figure 2B) . In contrast, the generation of ROS evoked by the soluble stimulus fMLP was significantly augmented in alv PMNs (p<0.01 compared to both ARDS and HV blood neutrophils; Figure 2C ), in keeping with the primed surface phenotype (CD11b high CD62L low) and F-actin redistribution to the cell periphery (data not shown). Incubating HV blood PMNs with ARDS lavage recapitulated the ARDS PMN survival phenotype and potentiated the oxidative burst (data not shown). Since ROS production (a pre-requisite for NET formation) was increased in agonist-stimulated ARDS-derived PMNs, and since excessive NET deployment may contribute to the pulmonary microvascular endothelial and alveolar damage observed in ARDS, we studied the capacity for NET formation. ARDS blood PMNs had a higher baseline capacity for compared to matched HV blood PMNs, again consistent with basal priming (Figure 2D) , but this did not reach statisitical significance. 
Conclusion
We present the first well-controlled comprehensive functional and phenotypic characterisation of highly pure alv PMNs and blood PMNs from ARDS patients and provide unique functional information describing the distinct PMN subsets present in the lungs of these patients. Collectively, our results show that these cells display enhanced survival (responsive to PI3K inhibition), preserved phagocytic capacity, but significantly enhanced extracellular ROS production in response to soluble stimuli (with the potential for enhanced tissue injury). 6 Targeting specific PMN subpopulations may be effective therapy for modulating the inflammation associated with ARDS.
